Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Chengdu China (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2016
NCT03050177
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Hunan Kelun Pharmaceutical Co., Ltd. | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Colorectal Neoplasms (Phase 3)

Hodgkin Disease (Phase 2)

Lymphoma (Phase 2)

Malnutrition (Phase 1)

Nasopharyngeal Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 28
  • # of Trial APIs: 28